Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.63 -2.16

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.52

Max

3.68

Pagrindiniai rodikliai

By Trading Economics

Pajamos

8.3M

-18M

Pardavimai

9.6M

10M

P/E

Sektoriaus vid.

22.5

60.149

Pelnas, tenkantis vienai akcijai

-0.1

Pelno marža

-177.89

Darbuotojai

69

EBITDA

9.5M

-18M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+223.22% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-91M

819M

Ankstesnė atidarymo kaina

5.79

Ankstesnė uždarymo kaina

3.63

Naujienos nuotaikos

By Acuity

60%

40%

280 / 340 reitingas Healthcare

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-17 23:56; UTC

News
Social Media

Micron Technology shares are lower in after-market trading amid a decline in India's smartphone shipments and ongoing memory cost pressures affecting margins.

2026-07-17 23:36; UTC

News

GameStop increased its stake in eBay to nearly 10%, acquiring 3.5 million shares for about $381 million. eBay shares are gaining in after-market trading.

2026-07-17 23:36; UTC

Macro News
News
ETF Constituents

Vanguard Information Technology ETF rises slightly in after-market trading, supported by gains in Microsoft, Analog Devices, Adobe, Qualcomm, and Snowflake.

2026-07-17 23:21; UTC

Social Media
News
Correlated Moves

Meta Platforms Inc. shares declined in after-market trading amid concerns over $125 billion to $145 billion in projected AI spending and slower development timelines.

2026-07-17 23:16; UTC

News

United Airlines reported record Q2 revenue of $17.7 billion, a 16% increase. Shares were little changed during after-market hours following the announcement.

2026-07-17 23:16; UTC

News
Social Media

PayPal Holdings Inc shares are lower in after-market trading amid reports of a potential bid, though analysts remain cautious about growth prospects.

2026-07-17 23:16; UTC

News
ETF Constituents
Macro News
Correlated Moves

GDX trades higher in after-market hours, supported by positive analysis and strong performance expectations amid rising geopolitical tensions and crude oil prices.

2026-07-17 23:06; UTC

News

Baidu Inc. partners with Apple to enhance its AI capabilities and pursues a dual-primary listing in Hong Kong, shares higher in after-market trading.

2026-07-17 23:06; UTC

ETF Constituents
News

Vanguard Growth ETF trades lower in after-market hours, continuing a downward trend. Top holdings META, AMAT, and LLY negatively impacted performance.

2026-07-17 20:07; UTC

News
Social Media

European Union approval is anticipated for the $55 billion acquisition of Electronic Arts by a group of investors, including Saudi Arabia's Public Investment Fund.

2026-07-17 20:07; UTC

News
Social Media

Tesla Inc shares are lower as investors await the earnings report on July 22. Concerns over Semi truck rollout and autonomous driving goals weigh on sentiment.

2026-07-17 20:07; UTC

Macro Event
Social Media
Correlated Moves
News

Broadcom shares declined to around $371.69 today, amid increased bearish sentiment and concerns over potential breakdowns below key support levels.

2026-07-17 20:07; UTC

News

Ethereum is trading lower as geopolitical tensions and rising oil prices heighten inflation concerns. Ongoing worries about tech valuations also impact its performance.

2026-07-17 20:07; UTC

News

Bitcoin is rising during Friday's session amid geopolitical tensions and rising oil prices, though it has pulled back from earlier session highs.

2026-07-17 20:07; UTC

News
Macro Event

Geopolitical tensions and rising oil prices support Bitcoin's gains during Friday's session, despite earlier pullbacks and regulatory scrutiny from former President Trump.

2026-07-17 20:03; UTC

News

J B Hunt shares are lower as freight shipments decline and inflationary pressures persist. The Cass Freight Index reported a 4.1% year-over-year drop in June.

2026-07-17 20:03; UTC

News
Social Media
Correlated Moves

Western Digital Corp shares are higher, supported by projected revenue growth of 43.7% and improved operating margins, despite earlier volatility and a pullback from session highs.

2026-07-17 20:03; UTC

News
Macro Event

Ulta Beauty is gaining as Evercore highlights its innovation amid positive consumer sentiment data, despite an earlier pullback from session highs.

2026-07-17 20:03; UTC

Correlated Moves
News
Social Media

Alphabet Inc. shares are declining amid reports of delays in the Gemini project rollout, overshadowing BMO's price target increase to $455.

2026-07-17 20:03; UTC

News
Correlated Moves
Social Media

Alphabet Inc shares are lower amid a securities fraud investigation and delays in its AI model rollout. BMO raised its price target to $455.

2026-07-17 20:02; UTC

News

Wynn Resorts Ltd is lower amid broader market declines and a negative outlook from StockStory, citing financial challenges and modest sales growth.

2026-07-17 20:01; UTC

News

NetApp Inc. shares are higher as StockStory highlights a $177.25 price target and strong growth in billings and earnings per share.

2026-07-17 19:56; UTC

News

Gilead Sciences shares are lower as the company missed full-year EPS estimates despite reporting $6.96 billion in revenue, reflecting heightened market volatility.

2026-07-17 19:56; UTC

News
Social Media

Apple Inc. is in early settlement discussions regarding an antitrust lawsuit. The company regained its status as the world's most valuable, surpassing Nvidia.

2026-07-17 19:52; UTC

News
Social Media
Correlated Moves

NVIDIA shares are declining amid a broader semiconductor sell-off and competitive concerns from Moonshot AI's new model. Apple has surpassed NVIDIA in market value.

2026-07-17 19:52; UTC

News
Correlated Moves

NXP Semiconductors NV is trading lower amid a broader market decline and rising pressures in the semiconductor industry, impacting its valuation narrative.

2026-07-17 19:52; UTC

News
Social Media
Correlated Moves

AMD declines today amid broader market losses, pulling back from session high.

2026-07-17 19:46; UTC

Social Media
News
Macro Event

Shares of American Airlines are lower today, trading around $15.03 amid increased bearish sentiment reflected in a rising put/call ratio of 1.61.

2026-07-17 19:46; UTC

Social Media
Correlated Moves
News

CSX shares are lower as Daniel Loeb exits his 500,000-share position, following significant cuts in other railroad investments amid regulatory scrutiny.

2026-07-17 19:46; UTC

News
Macro Event

Autodesk announces a collaboration with Amazon Web Services and raises revenue guidance to $8.5 billion, as shares gain during Friday's session.

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

223.22% į viršų

12 mėnesių prognozė

Vidutinis 11.83 USD  223.22%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

280 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat